JPML Weighs New Opioid MDL As McKinsey Suits Surge
By Jeff Overley (May 27, 2021, 8:23 PM EDT) -- New multidistrict litigation probably won't streamline dozens of cases accusing McKinsey & Co. of helping drugmakers aggressively market prescription opioids, but squeezing the cases into a long-running opioid MDL might be unfair, judges said Thursday.
During 30 minutes of oral arguments, members of the Judicial Panel on Multidistrict Litigation sounded skeptical about McKinsey's request that the cases be centralized in a new MDL near its New York City headquarters, but also wary of centralization within the existing MDL in Cleveland.
U.S. District Judge Matthew F. Kennelly, a JPML member who presides in Illinois, doubted McKinsey's contention that the Southern District of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!